SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Rivian Automotive, Inc. engages in the design, development, and manufacture of category-defining electric vehicles and accessories. It operates through following segments: Automotive, Software and Services. The company was founded by Robert J. Scaringe in June 2009 and is headquartered in Irvine, CA.

Rivian Automotive Inc - Ordinary Shares - Class A

Rivian Automotive Inc

Rivian is trending after announcing a 75 million-share public offering to raise approximately $1.5 billion, sparking a sharp decline as investors react to the dilution. While community sentiment is heavily polarized, the primary debate focuses on whether this capital raise is a necessary move to unlock government loan funding for factory expansion or a poorly timed decision that undermines recent stock momentum.

Navitas Semiconductor Corp. engages in the development of ultra-efficient gallium nitride (GaN) semiconductors. Its GaN power ICs integrate GaN power with drive, control and protection to enable charging, power density, and energy savings for mobile, consumer, enterprise, eMobility and new energy markets. The company was founded by Daniel Kinzer, Nick Fichtenbaum, Gene Sheridan, and Jason Zhang on August 12, 2020 and is headquartered in Torrance, CA.

Navitas Semiconductor Corp

Navitas Semiconductor is facing heightened volatility and selling pressure following a patent infringement lawsuit filed by Wolfspeed, which has triggered community debate over the company's long-term competitive position and legal risks. Investors are sharply divided between those viewing the pullback as a buying opportunity based on the stock's role in AI data center power infrastructure and others cautioning against overvaluation and potential dilution.

Penguin Solutions, Inc. engages in designing, building, and managing enterprise solutions. It operates through the following segments: Advanced Computing, Integrated Memory, and Optimized LED. The Advanced Computing segment offers platform solutions and services for artificial intelligence, high-performance computing, machine learning, advanced modeling, and the internet of things. The Integrated Memory refers to integrated memory solutions through the design and development. The Optimized LED segment comprises a broad portfolio of application-optimized LEDs. The company was founded in 1988 and is headquartered in Fremont, CA.

Penguin Solutions Inc.

Penguin Solutions is gaining significant attention following a strong earnings beat and raised guidance, fueled by robust demand for its AI infrastructure and integrated memory solutions. The community is actively debating the stock's potential as an AI factory partner versus concerns regarding its memory-focused business model and potential share dilution.

BioCryst Pharmaceuticals, Inc. is a biotechnology company. It engages in the provision of structure-guided drug design with the goal of developing oral small-molecule and protein therapeutics to target difficult-to-treat rare diseases. The company was founded by William M. Spencer III, Charles E. Bugg, and John A. Montgomery in 1986 and is headquartered in Durham, NC.

Biocryst Pharmaceuticals Inc.

Biocryst Pharmaceuticals is seeing significant market interest driven by potential buyout speculation and a shift toward a more capital-efficient model following the closure of its internal discovery laboratory. The community is actively debating the likelihood of an M&A catalyst, with traders closely tracking short interest and technical breakouts as they look for sustained momentum toward higher price levels.

Crinetics Pharmaceuticals, Inc. operates as a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The firm's product candidate, CRN00808, is an oral nonpeptide somatostatin agonist for the treatment of acromegaly. It is also developing other oral nonpeptide somatostatin agonists for neuroendocrine tumors and hyperinsulinism, as well as an oral nonpeptide ACTH antagonist for the treatment of Cushing's disease. The company was founded by R. Scott Struthers, Yun-Fei Zhu and Stephen F. Betz in 2008 and is headquartered in San Diego, CA.

Crinetics Pharmaceuticals Inc

Crinetics Pharmaceuticals is trending after Vertex Pharmaceuticals announced a definitive agreement to acquire the company for $10 billion in an all-cash deal. The community is actively discussing the massive valuation premium and the strategic validation the acquisition provides for the broader rare endocrine and obesity therapeutic landscape.

FuelCell Energy, Inc. engages in the business of developing, designing, producing, constructing, and servicing high temperature fuel cells for clean electric power generation. It operates through the following geographical segments: the United States, South Korea, and Europe. The company was founded by Bernard Baker and Martin G. Klein in 1969 and is headquartered in Danbury, CT.

Fuelcell Energy Inc

FuelCell Energy is trending as investors react to a significant share offering aimed at funding manufacturing expansion for the growing AI data center power market. While some in the community view the capital raise as a necessary step to scale operations and meet rising demand, many retail shareholders are expressing frustration over the dilutive impact on their positions and the company's long-term performance history.

One Stop Systems, Inc. engages in the design, manufacture, and marketing of computing modules and systems targeting edge deployments. It deals with the design and manufacture of high-performance customized computer and flash arrays, in-flight entertainment, and connectivity and value-added reseller with minimal customization. The company operates through the OSS and OSS Europe segments. One Stop Systems was founded by Stephen D. Cooper and Mark Gunn in 1998 and is headquartered in Escondido, CA.

One Stop Systems Inc

One Stop Systems is trending due to the convergence of its rugged edge AI hardware being positioned as a key component for defense and autonomous systems, alongside bullish community sentiment regarding potential index inclusion and upcoming contract catalysts. Investors are actively discussing the stock's role in the physical AI buildout and debating whether current pullbacks represent a strategic buying opportunity or a broader sector rotation.

Vertex Pharmaceuticals, Inc. is a global biotechnology company, which engages in the business of discovering, developing, manufacturing, and commercializing small molecule drugs for patients with serious diseases. The firm focuses on development and commercializing therapies for the treatment of cystic fibrosis, infectious diseases including viral infections such as influenza and bacterial infections, autoimmune diseases such as rheumatoid arthritis, cancer, inflammatory bowel disease and neurological disorders including pain and multiple sclerosis. The company was founded by Joshua S. Boger in 1989 and is headquartered in Boston, MA.

Vertex Pharmaceuticals, Inc.

Vertex Pharmaceuticals is trending following the major ten billion dollar all-cash acquisition of Crinetics Pharmaceuticals, a strategic move that significantly expands its pipeline into the rare endocrine and obesity landscape. Community discussion is heavily focused on how this deal serves as a broader validation for the sector's growth potential while prompting investors to reassess the company's long-term valuation alongside its existing robust clinical pipeline.

Occidental Petroleum Corp. engages in the exploration and production of oil and natural gas. It operates through the following segments: Oil and Gas, Chemical, and Midstream and Marketing. The Oil and Gas segment explores for, develops and produces oil and condensate, natural gas liquids, and natural gas. The Chemical segment manufactures and markets basic chemicals and vinyls. The Midstream and Marketing segment purchases, markets, gathers, processes, transports and stores oil, condensate, natural gas liquids, natural gas, carbon dioxide, and power. The company was founded in 1920 and is headquartered in Houston, TX.

Occidental Petroleum Corp.

Occidental Petroleum is actively trending as traders weigh the impact of renewed geopolitical tensions in the Strait of Hormuz against fluctuating ceasefire signals. Community discussion is heavily focused on the stock's sensitivity to oil supply disruptions, with many bulls interpreting recent price volatility as a long-term accumulation opportunity despite ongoing market uncertainty.

NVIDIA Corp. engages in the design and manufacture of computer graphics processors, chipsets, and related multimedia software. It operates through the following segments: Graphics Processing Unit (GPU) and Compute & Networking. The Graphics segment includes GeForce GPUs for gaming and PCs, the GeForce NOW game streaming service and related infrastructure, Quadro and NVIDIA RTX GPUs for enterprise workstation graphics, virtual GPU, or vGPU, software for cloud-based visual and virtual computing, automotive platforms for infotainment systems, and Omniverse Enterprise software for building and operating metaverse and 3D internet applications. The Compute & Networking segment consists of Data Center accelerated computing platforms and end-to-end networking platforms including Quantum for InfiniBand and Spectrum for Ethernet, NVIDIA DRIVE automated-driving platform and automotive development agreements, Jetson robotics and other embedded platforms, NVIDIA AI Enterprise and other software, and DGX Cloud software and services. The company was founded by Jen Hsun Huang, Chris A. Malachowsky, and Curtis R. Priem in April 1993 and is headquartered in Santa Clara, CA.

NVIDIA Corp

Nvidia is trending as investors debate the impact of rising competition from custom silicon development and sector-wide volatility, while sentiment remains divided between concerns over AI infrastructure spending and bullish confidence in its long-term market dominance. The community is actively discussing massive institutional buy-ins and potential breakout levels, with traders closely monitoring the stock's resilience against broader semiconductor sell-offs.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Why Elliott Sees Hidden Billions Inside Bio-Rad Laboratories

Elliott Management builds a stake in Bio-Rad (NYSE: BIO) to push for better performance, but family voting control could pose a hurdle.read more...

Bio-Rad to Participate in Upcoming Investor Conferences

Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced that the company will participate in the following...

Bio-Rad Laboratories (NYSE:BIO.B) Trading Down 12.8% - Time to Sell?

Bio-Rad Laboratories (NYSE:BIO.B) Trading Down 12.8% - Here's Why...

Bio-Rad Laboratories (NYSE:BIO.B) Shares Gap Down   - Should You Sell?

Bio-Rad Laboratories (NYSE:BIO.B) Shares Gap Down - Here's What Happened...

Bio-Rad Laboratories, Inc. (NYSE:BIO) Receives Average Rating of "Hold" from Analysts

Shares of Bio-Rad Laboratories, Inc. (NYSE:BIO - Get Free Report) have earned an average rating of "Hold" from the five brokerages that are presently covering the stock, MarketBeat.com reports. One research analyst has rated the stock with a sell recommendation, three have given a hold recommendat...

Unlocking Bio-Rad (BIO) International Revenues: Trends, Surprises, and Prospects

Explore how Bio-Rad's (BIO) revenue from international markets is changing and the resulting impact on Wall Street's predictions and the stock's prospects.

Wells Fargo & Company Has Lowered Expectations for Bio-Rad Laboratories (NYSE:BIO) Stock Price

Wells Fargo & Company decreased their target price on Bio-Rad Laboratories from $320.00 to $290.00 and set an "equal weight" rating for the company in a research note on Friday...

Bio-Rad Laboratories (NYSE:BIO) Shares Gap Down Following Weak Earnings

Bio-Rad Laboratories (NYSE:BIO) Shares Gap Down After Earnings Miss...

Bio-Rad Laboratories Q1 Earnings Call Highlights

Bio-Rad Laboratories (NYSE:BIO) reported first-quarter 2026 results that fell within its revenue guidance range, while management emphasized that geopolitical disruption in the Middle East and continued weakness in academic research demand are weighing on growth and profitability expectations for th...

Bio-Rad Laboratories (NYSE:BIO) Announces Earnings Results

Bio-Rad Laboratories (NYSE:BIO - Get Free Report) announced its quarterly earnings data on Thursday. The medical research company reported $1.89 earnings per share for the quarter, missing analysts' consensus estimates of $1.97 by ($0.08). The business had revenue of $592.10 million during the...

Bio-Rad Laboratories, Inc. engages in the development, manufacturing, and marketing of a portfolio of instruments, systems, reagents, and consumables. It operates through the following segments: Life Science and Clinical Diagnostics. The Life Science segment includes development, manufacturing, and marketing of instruments, systems, reagents, and consumables used to separate, purify, characterize, and quantify biological materials. The Clinical Diagnostics segment focuses on designing, manufacturing, marketing, and support of diagnostic test systems, informatics solutions, test kits, and specialized quality controls for clinical laboratories in the global diagnostics market. The company was founded by David S. Schwartz and Alice N. Schwartz in 1952 and is headquartered in Hercules, CA.

Bio-Rad Laboratories Inc. - Ordinary Shares - Class A

Bearish Sentiment

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Feed

News

Sentiment

Earnings

Fundamentals

Info

BIOBio-Rad Laboratories Inc. - Ordinary Shares - Class A

Fundamentals

Latest BIO News